KNG1 and angioedema: Drugs for the treatment of angioedema target the kallikrein/kinin system: the effect of BK can be inhibited by the bradykinin receptor (BKR)-2 inhibitor icatibant (65), and the kallikrein inhibitory antibody lanadelumab (13).